AMRX
Amneal Pharmaceuticals, Inc.
19.30$
-0.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.6% | +9.7% | +103.5% | +6.9% | -99.3% | +22,128.8% | -36.2% | -73.1% | +430.8% | -14.6% | +15.2% | |
| – | +25.1% | +29.7% | +39.1% | +199.1% | +50.8% | +17.8% | -4.4% | +2.9% | -4.5% | +3.0% | -5.3% | |
| – | – | – | -78.0% | +3,456.8% | -87.1% | -4.3% | +36.9% | +12.1% | -15.8% | +3.5% | +15.1% | |
| – | +66.1% | +46.3% | -28.2% | +1,665.3% | +117.7% | -80.4% | -12.3% | +17.4% | – | – | – | |
| – | – | – | – | – | -1,814.9% | – | – | – | – | – | – | |
| – | +47.9% | +6.2% | -8.3% | -15.0% | +0.4% | -36.5% | -22.8% | +89.8% | -23.6% | +8.4% | -6.6% | |
| – | +12.1% | -8.1% | -20.9% | +302.2% | -95.1% | +1,521.8% | -38.8% | -10.2% | -60.3% | -9.0% | +78.2% | |
| – | +6.2% | -22.3% | +87.1% | -51.2% | -100.0% | – | – | – | – | – | – | |
| – | +249,380.0% | -90.7% | -85.1% | -652.4% | -87.8% | -6.8% | +208.7% | +34.0% | -33.4% | +234.4% | – | |
| – | -20.6% | -20.4% | +51.7% | +70.0% | -105.6% | – | -100.6% | – | -72.8% | -917.2% | – | |
| – | -152.0% | -22.0% | +387.4% | – | -115.9% | – | -204.8% | -22.8% | +99.4% | -0.4% | -85.1% | |
| – | -258.4% | – | – | +248.9% | -146.8% | – | -146.5% | – | – | -69.8% | +907.2% | |
| – | -138.0% | – | – | +27.7% | -162.5% | – | -38.8% | -113.1% | – | -20.4% | +22.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.